Form 483

Kedrion Biopharma Inc. Form 483, 2026-05-21

FDA issued a Form 483 to Kedrion Biopharma Inc. on 2026-05-21 with 8 public-safe observations.

483· Form 483 issuedBiologics8 observations

Kedrion Biopharma Inc. · Melville, United States · Issued May 21, 2026

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 May 2026
21 CFR 211.105(a)

Identification of containers, lines, equipment

Cited by Scott T Ballard, Lu Deng, Malgorzata G Norton

21 May 2026
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Scott T Ballard, Lu Deng, Malgorzata G Norton

21 May 2026
21 CFR 211.180(e)(1)

Review of representative number of batches

Cited by Scott T Ballard, Lu Deng, Malgorzata G Norton

21 May 2026
21 CFR 211.184(c)

Individual inventory record

Cited by Scott T Ballard, Lu Deng, Malgorzata G Norton

21 May 2026
21 CFR 211.188(b)

Batch production and Batch Control Record Requirements

Cited by Scott T Ballard, Lu Deng, Malgorzata G Norton

Inspected site

KBKedrion Biopharma Inc.Melville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.105(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.180(e)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.184(c)Cited across public-safe Form 483 observations1x
21 CFR 211.188(b)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x
21 CFR 601.12(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere